---

Anaphylaxis Management

---

Pathophysiology (Brief)

---

Diagnosis - Clinical Criteria

1. Acute onset of illness with skin/mucosal involvement (hives, flushing, swollen lips/tongue) PLUS either respiratory compromise OR reduced BP/end-organ symptoms
2. Two or more of the following occurring rapidly after exposure to a likely allergen: skin/mucosal symptoms, respiratory compromise, reduced BP, or persistent GI symptoms
3. Reduced BP after exposure to a known allergen

---

Common Triggers

---

Clinical Manifestations

Note: Cardiovascular collapse can occur without skin features, particularly with insect sting anaphylaxis or perioperative reactions.

---

Management Algorithm

---

Step-by-Step Treatment

1. Immediate Actions (Simultaneous)

• Remove / stop the trigger (discontinue IV infusion, remove insect stinger)
• Call for help; activate emergency response if in community setting
• Positioning: supine with legs elevated (hypotension); left lateral decubitus (pregnancy); allow sitting up if respiratory distress or vomiting - do not stand the patient up suddenly
• Supplemental oxygen (high-flow, 100%)
• IV/IO access - large-bore peripheral line
• Continuous monitoring - cardiac, pulse oximetry

2. Epinephrine - First-Line, No Contraindications

Epinephrine is the sole first-line drug. There are no absolute contraindications. Antihistamines and corticosteroids are adjuncts only and must never precede or replace epinephrine.

• Adults: 0.3-0.5 mg (0.3-0.5 mL of 1:1000 / 1 mg/mL solution) IM in the lateral thigh (vastus lateralis)
• Children: 0.01 mg/kg of 1:1000 solution IM in the lateral thigh (max 0.5 mg)
• Can be repeated every 5-10 minutes - up to 30% of patients require more than one dose
• IM into the vastus lateralis achieves peak plasma concentration in ~8 minutes vs. ~34 minutes subcutaneously - subcutaneous route is no longer recommended

• Prepare: 1 mg in 1000 mL NS or D5W → concentration 1 mcg/mL
• Adults: start at 1 mcg/min, titrate up to maximum 10 mcg/min
• Children: 0.1 mcg/kg/min, up to 1.5 mcg/kg/min
• Requires cardiac monitoring; use central line if possible (extravasation causes tissue necrosis)

• α1: vasoconstriction, reduces mucosal edema
• β1: positive inotropy and chronotropy
• β2: bronchodilation, stabilizes mast cells/basophils and reduces further mediator release

3. IV Fluids (Circulatory Collapse)

• Large volumes may be required - up to 1-2 L bolus initially in adults; repeat as needed
• Crystalloids (normal saline or Ringer's lactate) are first choice
• Massive fluid shifts can rapidly reduce intravascular volume due to increased capillary permeability

4. Airway Management

• Maintain airway patency - early intubation if laryngeal edema is developing
• If laryngeal edema does not respond rapidly to epinephrine: cricothyrotomy or tracheotomy
• Nebulized albuterol for persistent bronchospasm:
  • Adults/children: 2.5 mg in 3 mL NS, repeat as needed or continuous
  • Add ipratropium: adults 0.5 mg; children 0.25 mg in 3 mL NS

5. Adjunct Medications (Secondary - After Epinephrine)

Corticosteroids have no significant immediate effect and do not reliably prevent biphasic reactions, but are commonly given. They should never delay epinephrine. - Washington Manual

Antihistamines relieve skin symptoms and may shorten reaction duration but have no effect on cardiovascular or respiratory components.

6. Refractory Anaphylaxis / Vasopressor Support

---

Special Situations

Beta-Blocker Use

ACE Inhibitor Use

Radiocontrast Media Premedication

• Prednisone 50 mg oral at 13 h, 7 h, and 1 h before
• Diphenhydramine 50 mg oral 1 h before
• Consider ephedrine 25 mg oral 1 h before
• Consider H2 antagonist (famotidine 20 mg) 3 h before

Pregnancy

---

Biphasic Reactions

• Occur in up to 20% of anaphylaxis cases - symptoms recur without re-exposure to the trigger
• Most occur within 8 hours, but can be delayed up to 72 hours
• Risk factors: hypotension, wide pulse pressure, unknown trigger, >1 epinephrine dose, prior anaphylaxis, delayed epinephrine administration
• Corticosteroids have not been shown to reliably prevent biphasic reactions

---

Disposition

---

Discharge Instructions

1. Epinephrine auto-injector (EpiPen) - 2 devices prescribed; demonstrate use
2. Individualized anaphylaxis action plan in writing
3. Allergen avoidance counseling
4. Medical ID (bracelet/wallet card) for known trigger
5. Allergist/immunologist referral - for trigger workup, venom immunotherapy eligibility, and long-term management

---

Key Points Summary

• Epinephrine IM (lateral thigh) is always first-line - give it early, give it without hesitation
• Studies show only ~30% of prehospital patients and 50-70% of ED patients with anaphylaxis actually receive epinephrine - this is a significant care gap
• Antihistamines and steroids are adjuncts and must not delay or replace epinephrine
• Beta-blocker patients may need glucagon for refractory bronchospasm/hypotension
• Observe for biphasic reactions; discharge planning must include auto-injector prescription and follow-up

---

• ROSEN's Emergency Medicine: Concepts and Clinical Practice, Chapter 106
• Goldman-Cecil Medicine, Chapter 233 (Schwartz & Castells)
• Washington Manual of Medical Therapeutics, Chapter on Allergy/Immunology
• Textbook of Family Medicine 9e, Chapter 19

---

Anaphylaxis: Diagnosis and Management

---

1. Definition

---

2. Diagnosis

Anaphylaxis is primarily a CLINICAL diagnosis

---

NIAID/FAAN + WAO Diagnostic Criteria (Box 106.5, Rosen's)

• Respiratory compromise (dyspnea, wheeze, stridor, hypoxemia)
• Reduced BP or end-organ symptoms (hypotonia, syncope, incontinence)

• Skin/mucosal involvement (hives, flushing, swollen lips/tongue)
• Respiratory compromise (dyspnea, wheeze, stridor, hypoxemia)
• Reduced BP or associated symptoms (syncope, collapse)
• Persistent GI symptoms (cramping, vomiting)

• Adults: systolic BP <90 mmHg or >30% drop from baseline
• Infants/children: age-specific low systolic BP

Key point: Criterion 2 catches anaphylaxis without skin features - this occurs in cardiovascular collapse from insect stings or perioperative reactions and is frequently missed.

---

Clinical Manifestations by System

Note: In infants and children, hypotension is uncommon; skin and respiratory features predominate.

---

Diagnostic Testing (Supportive, Not Acute)

"The absence of an elevated tryptase level does not exclude anaphylaxis." - Washington Manual

---

Differential Diagnosis (Harrison's 22E, Table 364-1)

---

3. Management

Management Algorithm

---

STEP 1 - Immediate Simultaneous Actions

• Remove/stop the trigger (stop IV infusion, remove insect stinger, tourniquet proximal to sting site)
• Call for help
• Position the patient:
  • Hypotension → supine, legs elevated
  • Respiratory distress/vomiting → allow comfortable position, elevate legs if possible
  • Pregnancy → left lateral decubitus (prevents vena cava compression)
  • Never stand patient up suddenly - can cause fatal cardiovascular collapse
• Supplemental high-flow oxygen (100%)
• Large-bore IV access (16-18 gauge preferred)
• Monitoring: continuous cardiac, BP, pulse oximetry

---

STEP 2 - Epinephrine (FIRST-LINE - No Contraindications)

Epinephrine is the sole first-line drug. Delay is associated with hypoxic encephalopathy and death. There are NO absolute contraindications in anaphylaxis.

• Repeat every 5-10 minutes - up to 30% need more than one dose
• IM into the thigh reaches peak plasma level in ~8 minutes vs ~34 minutes subcutaneously
• Subcutaneous and inhaled routes are no longer recommended
• Auto-injectors (EpiPen 0.3 mg; EpiPen Jr 0.15 mg) are acceptable alternatives

• Prepare: 1 mg in 1000 mL NS or D5W → 1 mcg/mL concentration
• Adults: start 1 mcg/min, titrate to max 10 mcg/min
• Children: 0.1 mcg/kg/min, titrate to max 1.5 mcg/kg/min
• Requires cardiac monitoring; use central line if possible (extravasation → tissue necrosis)

---

STEP 3 - IV Fluids

• Start rapid isotonic crystalloid (normal saline):
  • Adults: 1000 mL IV in the first 5 min; several liters may be needed
  • Children: 20-30 mL/kg in increments
• Massive fluid shifts occur from capillary leak - aggressive resuscitation may be required

---

STEP 4 - Airway Management

• Ensure patent airway at all times
• Early endotracheal intubation if laryngeal edema is developing - do not wait for full obstruction
• If laryngeal edema does not respond rapidly to epinephrine: cricothyrotomy or tracheotomy
• Nebulized bronchodilators for bronchospasm:
  • Albuterol: 2.5 mg in 3 mL NS (adults and children), repeat or continuous
  • Ipratropium: 0.5 mg (adults) / 0.25 mg (children) in 3 mL NS

---

STEP 5 - Second-Line Adjuncts (AFTER Epinephrine - Never Before)

Corticosteroids have no significant immediate effect and reliable evidence showing they prevent biphasic reactions is lacking. They must never precede or delay epinephrine.

---

STEP 6 - Refractory Cases / Special Situations

• Epinephrine may have blunted effect
• Glucagon 1-5 mg IV bolus (adults) / 20-30 mcg/kg max 1 mg (children) over 5 min, then 5-15 mcg/min infusion
• Glucagon acts via cAMP pathway, bypassing beta-receptors
• Pre-treat with antiemetic - nausea/vomiting are common side effects

---

4. Biphasic Reactions

• Occur in up to 20% of patients - recurrence of anaphylaxis without re-exposure
• Most within 8 hours, rarely up to 72 hours
• Corticosteroids have not been shown to reliably prevent biphasic reactions

• Hypotension at presentation
• Wide pulse pressure
• Unknown trigger

• 1 dose of epinephrine required

• Prior history of anaphylaxis
• Delayed epinephrine administration
• Cutaneous signs and symptoms

---

5. Disposition

---

6. Discharge - Mandatory Steps

1. Two epinephrine auto-injectors prescribed - demonstrate how to use them
2. Written individualized anaphylaxis action plan
3. Allergen avoidance education
4. Medical ID (bracelet or wallet card) listing known trigger
5. Allergist/immunologist referral - for allergen confirmation (skin/IgE testing), venom immunotherapy eligibility, and long-term desensitization options

---

Summary - Key Priorities

---

• ROSEN's Emergency Medicine, Chapter 106 (Box 106.5, 106.7)
• Harrison's Principles of Internal Medicine 22E (2025), Chapter 364
• Goldman-Cecil Medicine, Chapter 233
• Washington Manual of Medical Therapeutics, Allergy/Immunology chapter

---

Sinus Bradycardia: Evaluation and Management

---

1. Definition and ECG Criteria

• Normal P-wave morphology (upright in I, II; inverted in aVR)
• Fixed P-P interval = R-R interval (each P followed by a QRS)
• PR interval normal (0.12-0.20 s)
• Rate < 60 bpm

Rates of 45-50 bpm at rest can be physiologically normal in athletes and during sleep. A rate < 40 bpm is more specific for significant sinus node dysfunction (SND).

---

2. Causes

Physiologic (Normal) Causes

• Well-conditioned athletes (high vagal tone)
• Sleep, rest
• Young adults with elevated resting vagal tone

Medical Conditions

Drugs Causing Sinus Bradycardia (Goldman-Cecil / Harrison's)

Note: Beta-blocker eye drops for glaucoma are a frequently overlooked cause of systemic bradycardia.

---

3. Spectrum of Sinus Node Dysfunction (SND)

---

4. Clinical Features and Symptoms

• Fatigue, exercise intolerance (most common, often underappreciated)
• Dizziness, presyncope, syncope (particularly in tachy-brady or severe pauses)
• Palpitations (in tachy-brady syndrome - the tachyarrhythmia phase)
• Worsening heart failure (chronotropic incompetence reducing cardiac output)
• Cognitive impairment (in elderly)

Asymptomatic sinus bradycardia has not been associated with adverse outcomes and does not typically warrant treatment.

---

5. Evaluation

Step-by-Step Approach (2018 ACC/AHA/HRS Guideline)

Step 1 - History and Physical Exam

• Full medication review (drugs most common reversible cause)
• Symptoms: onset, duration, correlation with activity/rest, syncope
• Exertional symptoms (suggest chronotropic incompetence)
• Associated conditions: thyroid disease, sleep apnea, Lyme exposure, recent MI

Step 2 - 12-Lead ECG

• Confirm sinus bradycardia
• Assess for AV block (often coexists with SND)
• Look for inferior MI pattern (RCA/SA nodal artery ischemia)
• PR interval prolongation, bundle branch block

Step 3 - Laboratory Tests

Step 4 - Echocardiography (Class IIa)

• Evaluate for structural heart disease (cardiomyopathy, valvular disease, wall motion abnormalities)
• Assess LV/RV function
• Look for infiltrative disease (amyloid, sarcoid)

Step 5 - Ambulatory ECG Monitoring (Class I for symptomatic patients)

Step 6 - Exercise Stress Testing (Class IIa)

• Used to assess chronotropic incompetence
• Failure to reach 80% of age-predicted maximum HR = chronotropic incompetence
• Also useful for exertion-related symptoms

Step 7 - Advanced Imaging (Class IIa)

• Cardiac MRI (sarcoidosis, amyloid, myocarditis)
• Cardiac CT (ACHD, structural)

Step 8 - Electrophysiology Study (EPS) (Class IIb - limited role)

• Not recommended as a primary diagnostic tool for SND
• May be useful when EPS is already indicated for AV block or syncope
• Can measure sinus node recovery time (SNRT) and sinoatrial conduction time

---

6. Management

---

Acute / Emergency Management

Atropine is ineffective in post-cardiac transplant patients because the transplanted heart is denervated.

Chronic Management

Step 1 - Remove/Treat Reversible Causes

• Stop or reduce offending drugs (beta-blockers, CCBs, digoxin, amiodarone)
• Treat hypothyroidism, sleep apnea, Lyme disease, ischemia
• Correct electrolytes
• If drug is medically necessary, consider pacemaker to allow continued use

Step 2 - Asymptomatic Sinus Bradycardia

• Observe - no treatment required
• Permanent pacing is Class III (Harm) for asymptomatic sinus bradycardia

Step 3 - Symptomatic SND with Confirmed Symptom-Rhythm Correlation

Atrial-based pacing is preferred over single-chamber ventricular pacing - reduces incidence of AF, pacemaker syndrome, and heart failure.

Pharmacologic Options (Limited Role)

• Oral theophylline (methylxanthine): Class IIb - may increase HR and improve symptoms; used as trial when symptom-rhythm correlation is uncertain, or as bridge/alternative when patient declines PPM
• Terbutaline (beta-agonist): Occasionally used as temporary bridge when PPM must be delayed (e.g., active infection)

---

7. Special Situations

---

8. Summary Approach

Sinus Bradycardia Found
        ↓
Symptomatic? (fatigue, dizziness, syncope, exercise intolerance)
     ↙              ↘
   NO               YES
Observe       Review medications → Stop offending drug if possible
              Check TSH, electrolytes, ECG for MI
              Echo (if structural disease suspected)
              Ambulatory monitor for symptom-rhythm correlation
                    ↓
              Symptoms correlate with bradycardia?
                 ↙              ↘
               YES            UNCERTAIN
          Permanent          Oral theophylline
          Pacemaker          trial → If responds → PPM
          (Class I)          If not → Observe

---

• ROSEN's Emergency Medicine, Chapter 65
• Harrison's Principles of Internal Medicine 22E (2025), Chapter 251 (Figure 251-3)
• Goldman-Cecil Medicine, Chapter 51 (Table 51-3)
• Fuster and Hurst's The Heart 15E, Chapter 38 (Figures 38-6, 38-7 - ACC/AHA/HRS 2018 algorithms)
• Harrison's 22E, Chapter 251 - Medical Conditions and Medications Associated with SND

---

Bradycardia: Complete Overview

---

1. Definition

1. Depression of the sinoatrial (SA) node (impaired impulse generation)
2. Conduction system block (impaired impulse transmission - SA exit block, AV block, infranodal block)

---

2. Classification of Bradyarrhythmias

Bradycardia
├── SA Node Level
│   ├── Sinus bradycardia
│   ├── Sinus pause / arrest
│   ├── Sinoatrial exit block (1st, 2nd, 3rd degree)
│   ├── Sick sinus syndrome (SSS)
│   └── Tachy-brady (bradycardia-tachycardia) syndrome
│
└── AV Conduction Level
    ├── First-degree AV block
    ├── Second-degree AV block
    │   ├── Mobitz Type I (Wenckebach) - AV nodal
    │   └── Mobitz Type II - Infranodal
    ├── High-grade (advanced) AV block
    └── Third-degree (complete) AV block

---

3. SA Node Disorders

Sinus Bradycardia

• Rate < 60 bpm (Braunwald: < 50 bpm is the stricter criterion)
• Normal P-wave morphology, constant PR interval, P:QRS = 1:1
• Often physiologic in athletes, during sleep, with high vagal tone
• Pathologic with hypothyroidism, drugs, ischemia (inferior MI), sick sinus syndrome

Sinus Arrest / SA Exit Block

• Sinus arrest: SA node fails to generate impulse → absent P wave, pause not a multiple of P-P interval
• SA exit block: SA fires but impulse blocked before reaching atrium → pause is a multiple of baseline P-P interval (e.g., 2:1, 3:1 block patterns)
• Both can cause escape rhythms if prolonged (junctional or ventricular)

Sick Sinus Syndrome (SSS)

• Group of disorders from disease of SA node and surrounding tissue
• Includes: sinus bradycardia, sinus arrest, SA exit block, chronotropic incompetence
• Most common in older adults (fibrotic degeneration)
• Associated with cardiomyopathies, connective tissue diseases, drugs

Tachy-Brady Syndrome

• Alternating bradyarrhythmia (sinus arrest/pause) and tachyarrhythmia (usually atrial fibrillation)
• The long pause is most evident after AF terminates
• Symptoms include both palpitations (tachycardia phase) and syncope/presyncope (bradycardia phase)

---

4. AV Conduction Blocks

First-Degree AV Block

Second-Degree AV Block

When the ratio is exactly 2:1, type cannot be distinguished without longer strip - a prolonged PR makes Mobitz I more likely; wide QRS makes Mobitz II more likely.

High-Grade / Advanced AV Block

• Two or more consecutive P waves fail to conduct
• Between 2nd and 3rd degree block
• Usually treated as third-degree block

Third-Degree (Complete) AV Block

---

5. Causes of Bradycardia

Common Medical Causes

Drugs Causing Bradycardia

---

6. Clinical Features

---

7. Evaluation

Initial Assessment

1. 12-lead ECG - identify the rhythm, P:QRS relationship, PR interval, QRS width
2. Vital signs - BP, SpO2, signs of hemodynamic compromise
3. History - medications, symptoms, exertion, syncope, prior cardiac history
4. Labs - TSH, electrolytes (K+, Ca2+, Mg2+), digoxin level, blood glucose, Lyme serology if indicated

Further Workup (Outpatient / Stable)

• Echocardiogram - structural heart disease, cardiomyopathy, infiltrative disease (Class IIa)
• Ambulatory ECG monitoring - Holter (24-48 h), extended event recorder (up to 30 days), implantable loop recorder (up to 3 years) for infrequent/unexplained syncope
• Exercise stress test - chronotropic incompetence, exertion-related symptoms (Class IIa)
• Cardiac MRI - suspected sarcoid, amyloid, myocarditis (Class IIa)
• Electrophysiology study (EPS) - limited role for SND; more useful for unexplained syncope, suspected infranodal block (Class IIb)

---

8. Management

Acute Symptomatic Bradycardia (ACLS Approach)

• Hypotension, altered consciousness, chest pain, signs of shock, acute heart failure

Step 1 - Atropine (First-Line)

Step 2 - If Atropine Fails / Infranodal Block

Step 3 - Treat Reversible Causes

• Stop/reduce offending drugs
• Treat acute MI (reperfusion), hypothyroidism, hyperkalemia, Lyme disease, hypoxia
• Correct electrolytes

---

Chronic Management - Pacemaker Indications

Sinus Node Dysfunction

AV Block

Pacing Mode Selection (ACC/AHA/HRS 2018)

Atrial-based pacing is preferred over single-chamber ventricular pacing - reduces AF incidence, pacemaker syndrome, and heart failure.

---

9. Summary Table - Quick Reference

---

• ROSEN's Emergency Medicine, Chapter 65 (Dysrhythmias)
• Braunwald's Heart Disease 2 Vol Set, Chapter 68 (Bradyarrhythmias)
• Goldman-Cecil Medicine, Chapter 51, Table 49-8
• Harrison's Principles of Internal Medicine 22E (2025), Chapter 251 (Fig. 251-3)
• Fuster and Hurst's The Heart 15E, Chapter 38 (ACC/AHA/HRS 2018 Guideline algorithms)
• Miller's Anesthesia 10E, Chapter 32 (ACLS bradycardia)

---

Can Hypotension Cause Bradycardia?

---

The Normal Response to Hypotension: Reflex Tachycardia

Hypotension → ↓ baroreceptor firing → ↑ sympathetic outflow + ↓ parasympathetic tone → tachycardia + vasoconstriction → restored BP

---

Mechanisms Where Hypotension Co-exists With (or Causes) Bradycardia

1. Vasovagal (Neurocardiogenic) Syncope - Most Common

• Prolonged upright posture or emotional trigger → blood pools in lower extremities → ↓ venous return → ↓ intracardiac volume
• Arterial baroreceptors sense the fall in BP and appropriately trigger sympathetic activation (tachycardia, increased contractility)
• However, mechanoreceptors (stretch receptors) in the wall of the left ventricle respond to the underfilled, vigorously contracting ventricle by sending paradoxical signals via unmyelinated vagal C fibers
• This triggers a paradoxical surge in parasympathetic tone → bradycardia + vasodilation + hypotension
• The individual becomes lightheaded and may lose consciousness

• Cardioinhibitory: predominant bradycardia (HR drops sharply, even to asystole briefly)
• Vasodepressor: predominant vasodilation/hypotension with little bradycardia
• Mixed: both occur together (most common)

"Pressure receptors in the wall of the left ventricle respond by sending signals that trigger paradoxical bradycardia and decreased contractility, resulting in sudden marked hypotension." - Ganong's Review of Medical Physiology

---

2. Bezold-Jarisch Reflex - A Core Physiology Mechanism

• Trigger: Chemoreceptors and mechanoreceptors in the left ventricular wall sense noxious stimuli (ischemia, reperfusion, chemical irritants, ventricular underfilling)
• Receptor type: 5-HT3 (serotonin) receptors on unmyelinated vagal C fibers
• Pathway: Afferent signal travels via vagal C fibers → brainstem → ↑ efferent parasympathetic output
• Result: Bradycardia + hypotension + coronary artery dilation

"The Bezold–Jarisch reflex responds to noxious ventricular stimuli... by inducing the triad of hypotension, bradycardia, and coronary artery dilatation." - Miller's Anesthesia 10E

"Activation of 5-HT3 receptors... in response to systemic hypotension increases efferent vagal signaling, producing bradycardia, reduced cardiac output, and worsened hypotension." - Barash Clinical Anesthesia

---

3. Cushing Reflex (Neurogenic - Raised ICP)

---

4. Inferior / Right Ventricular Myocardial Infarction

• RCA occlusion causes ischemia of the SA node (60% supplied by RCA) and AV node (85-90% supplied by RCA)
• Simultaneously, the Bezold-Jarisch reflex is activated by ischemic ventricular receptors
• Result: Bradycardia (sinus or AV block) + hypotension (from RV failure and reduced preload)
• Atropine is used for the bradycardia; IV fluids are critical for RV infarct hypotension
• This is one of the most clinically important hypotension-bradycardia combinations

---

5. Neuraxial (Spinal/Epidural) Anesthesia

• Sympathetic blockade → vasodilation → hypotension
• Reduced venous return → ventricular underfilling → Bezold-Jarisch reflex → bradycardia
• Can be severe; treated with atropine, ephedrine, or phenylephrine
• Ondansetron (5-HT3 antagonist) may reduce the risk by blocking the reflex receptor

---

6. Carotid Sinus Hypersensitivity

• Pressure on the carotid sinus (tight collar, head turning) → exaggerated baroreceptor firing → paradoxical ↑ vagal tone → bradycardia + hypotension
• Cardioinhibitory type: primarily bradycardia
• Vasodepressor type: primarily hypotension

---

7. Drugs

---

Summary: When Do You See Hypotension + Bradycardia Together?

---

Clinical Importance

• Hypotension + bradycardia is a dangerous combination because both reduce cardiac output simultaneously (CO = HR × SV)
• In hemorrhagic shock, paradoxical bradycardia signals decompensation - a very ominous sign
• Do not give atropine alone for bradycardia in the context of inferior MI with hypotension - you must also treat the RV infarct and ischemia
• In spinal anesthesia, treating the hypotension (with phenylephrine or fluids) often breaks the Bezold-Jarisch cycle and resolves the bradycardia simultaneously

---

• Ganong's Review of Medical Physiology 26E, Chapter 32 (Bezold-Jarisch Reflex, Vasovagal Syncope)
• Miller's Anesthesia 10E, Chapter 4 (Bezold-Jarisch Reflex)
• Barash Clinical Anesthesia 9E, Chapter 35 (Neuraxial anesthesia bradycardia)
• Morgan & Mikhail's Clinical Anesthesiology 7E
• Katzung Basic & Clinical Pharmacology 16E (5-HT3 receptor-mediated Bezold-Jarisch)